India's Pharmaceutical Industry Is Entering a New Era of Growth
The pharmaceutical industry in India has emerged as one of the most significant pillars of the international healthcare landscape. Famous for its mass production of generics, vaccines and active pharmaceutical ingredients, India is shifting towards high value segments including biologics, biosimilars, complex generics, innovative drugs, clinical studies and pharmaceutical technologies.
India is among the largest drug manufacturers in the world and exports drugs to more than 200 countries. The sector is poised to grow and, according to Invest India, the Indian pharmaceutical market could be worth about USD 130 billion by 2030.
However, the growth of the India pharmaceutical industry presents opportunities to Japanese companies that are not limited to tapping into the Indian market alone. The manufacturing scale, scientific expertise and rising healthcare requirements in India provide an opportunity to leverage Japan's strengths in research, advanced manufacturing, quality systems, biotechnology and innovative healthcare solutions.
These strengths could form the basis of future India Japan pharmaceutical cooperation.
Why India Is a Global Pharmaceutical Manufacturing Hub
The traditional strength of the Indian pharma sector lies in effective manufacturing on a massive scale. The generic drugs, vaccines, formulations and pharmaceutical products produced by Indian companies find their way into global markets.
These capabilities of the sector have become a solid base for partnerships between Indian and international pharma companies. India has accumulated know how in regulatory compliance, pharma manufacturing and international logistics, and its substantial contingent of scientists and technical specialists provides the sector with possibilities for further expansion.
But at present, the industry is changing the paradigm of the manufacturing driven business model.
The new stage of the sector's development will be based on biopharmaceuticals, biosimilars, complex generics, specialty drugs, research and development and high tech healthcare solutions.
Pharmaceutical Investment Opportunities in India
There are opportunities being created across the pharmaceutical value chain in relation to India's rising healthcare demands. The rising demand for medicines, increase in healthcare expenditure and greater provision of advanced medical facilities will contribute to long term growth in the industry.
In addition, there are government policies that are encouraging investments and innovation. One such programme is the Promotion of Research and Innovation in Pharma MedTech (PRIP), which has an outlay of INR 5,000 crore. It is aimed at several areas such as new chemical entities, new biological entities, complex generics, biosimilars, precision medicine, orphan drugs, medical devices and drugs for antimicrobial resistance.
Given the focus of these policies, they present significant opportunities for foreign firms in research infrastructure, industry led R&D, technology and industrial academia collaboration.
Japanese companies can thus use India as a base for production, research, technology and access to growing healthcare markets.
India Japan Pharmaceutical Cooperation Is Gaining Momentum
The healthcare sector between India and Japan has seen increasing cooperation in recent times. This growing relationship is gaining more relevance as the two countries attempt to enhance healthcare access, build robust supply chains and promote technological collaborations.
One significant development in this regard has been the Third Japan India Healthcare Joint Committee, which took place in New Delhi in May 2026. Some of the key areas of cooperation that emerged from the discussion included the prevention, diagnosis, treatment and rehabilitation of non communicable diseases; robust supply chains and access to high quality medical products and services; digital health; and human resources development and exchanges.
Clearly, the wide scope of this relationship is evidence of the fact that India Japan healthcare cooperation goes well beyond traditional drug manufacturing.
For businesses, it means that there is a much broader scope of collaboration in this space, including technology, healthcare infrastructure, research and skills development.
Key Opportunities for Japanese Pharmaceutical Companies in India
There are many possibilities that Japanese pharmaceutical companies in India could explore within the country's growing pharmaceutical industry.
Pharmaceutical manufacturing and CDMO relationships are one possibility, where companies may leverage India's manufacturing experience and Japan's expertise in quality, accuracy and processes.
Active pharmaceutical ingredients and key starting materials are another strategically vital area. Both India and Japan import certain products used in pharmaceuticals from other countries. As per JETRO, there is a possibility for Indian companies to increase manufacturing capacity while Japanese companies can provide advanced technologies such as fermentation technologies.
Biologics and biosimilars are other areas where Japanese pharmaceutical companies can find possibilities. India has built up its capabilities in pharmaceutical manufacturing and the development of biosimilars, while Japanese companies have expertise in research, technologies and healthcare markets.
There are other opportunities in clinical research, drug discovery, precision medicine, digital health and healthcare technology. Japanese pharmaceutical companies can innovate through collaborations with Indian startups, universities and research institutions.
Strengthening India Japan Pharmaceutical Supply Chains
The global healthcare industry is increasingly prioritizing robustness and diversity in the supply chain of medicines and drugs. The Indian and Japanese economies have unique strengths that can help achieve this aim.
India has strengths in production capacity, pharmaceutical knowledge, scientific know how and exporting capabilities. Japan has strengths in technology, research and development, quality manufacturing and expertise in developing complex healthcare solutions.
The collaboration can take many different forms, such as joint ventures, technology transfer, manufacturing in India, drug development, research and development collaboration, supplier development and employee training.
But the possibilities go even further beyond multinational pharmaceutical corporations. Indian startups, specialized manufacturing companies, research institutes and healthcare technology firms can be valuable collaborators for Japanese organizations.
JIBB and India Japan Pharmaceutical Business Collaboration
Entering the Indian pharma market entails more than recognizing an opportunity. There is a need to have information on market dynamics, the regulatory framework, potential partners, regional ecosystems and local business culture.
This is where the Japan India Business Bureau (JIBB) comes in to facilitate cross border activities.
Pharmaceuticals is among JIBB's eight priority sectors, with its sector activity encompassing opportunities such as active pharmaceutical ingredients, oncology formulations and clinical trials.
JIBB is a platform that brings together various business actors, including institutions from India and Japan, to promote market entry and partnerships.
For Japanese pharmaceutical companies looking at India, it presents an opportunity to interact with potential partners and establish commercial relationships.
The Future of Pharmaceuticals in India
India's pharmaceutical industry has transformed itself from a manufacturing centre for generics into a wider ecosystem of life sciences and innovation. Expansion of biotechnology, biosimilar production, advanced manufacturing processes, clinical trials, digital health and pharmaceutical R&D has presented new opportunities for both domestic and foreign companies.
India offers a strategic partner for Japan in developing resilient healthcare supply chains and increasing innovation within the pharmaceuticals field.
India stands to benefit from collaboration with Japan through access to cutting edge technology, expertise in research, funding and global healthcare networks.
Future collaboration between India and Japan in the pharmaceutical sector will be determined by leveraging these complementary strengths to develop sustainable partnerships and innovations in global healthcare.
Frequently Asked Questions
1. Why is India's pharmaceutical industry important globally?
India is one of the world's leading pharmaceutical producers by volume and exports medicines to more than 200 countries. Its strengths include generic medicines, vaccines, formulations and pharmaceutical ingredients.
2. What are the main pharmaceutical investment opportunities in India?
Key opportunities include pharmaceutical manufacturing, APIs, biosimilars, biologics, complex generics, clinical research, drug discovery, precision medicine and healthcare technology.
3. Why are Japanese pharmaceutical companies interested in India?
India offers a large healthcare market, established manufacturing capabilities, scientific talent and opportunities to participate in global pharmaceutical supply chains. Japanese companies can complement these strengths with advanced technology, research expertise and quality focused manufacturing.
4. What is the India Japan Healthcare Joint Committee?
It is a bilateral platform for strengthening healthcare cooperation between India and Japan. Its 2026 meeting focused on non communicable diseases, resilient supply chains, digital health and human resource development and exchanges.
5. What opportunities exist for Japanese companies in Indian pharmaceuticals?
Japanese companies can explore manufacturing, APIs, biosimilars, clinical research, R&D, technology partnerships, joint ventures and pharmaceutical supply chain development.
6. What is PRIP in India's pharmaceutical sector?
PRIP stands for the Promotion of Research and Innovation in Pharma MedTech. The INR 5,000 crore scheme is designed to strengthen pharmaceutical and MedTech research and encourage innovation in areas including complex generics, biosimilars, new therapies and precision medicine.
7. How does JIBB help Japanese pharmaceutical companies enter India?
JIBB facilitates India Japan business partnerships and identifies opportunities in pharmaceuticals including APIs, oncology formulations and clinical trials. Its broader services include market entry support, partnership facilitation and cross border business collaboration.
8. Is India suitable for pharmaceutical manufacturing and R&D?
Yes. India combines an established pharmaceutical manufacturing ecosystem with a large scientific talent pool, growing domestic demand and increasing policy support for pharmaceutical research and innovation.
